Lung Diseases | Boehringer Ingelheim
Lung Diseases
Boehringer Ingelheim has 100 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Latest Articles on Lung Diseases
Targeting the vicious vortex of bronchiectasis
Dr Wiebke Sauter, Clinical Development Lead, explores the unmet needs for people living with bronchiectasis.
[Read more](/content/human-health/lung-diseases/phase-iii-airtivity-trial "Teaser headline Targeting the vicious vortex of bronchiectasis"/index.html)
[How to improve symptoms and quality of life for people living with bronchiectasis.](/content/human-health/lung-diseases/phase-ii-trials-patients-bronchiectasis "Phase II trials for patients with bronchiectasis"/index.html)
How to improve symptoms and quality of life for people living with bronchiectasis.
Learn more about their unmet needs and the viscous vortex.
[100-year anniversary](/content/human-health/lung-diseases/100-year-anniversary-bi-respiratory-care "100-year anniversary of BI in respiratory care"/index.html)
100-year anniversary
In 1921, Boehringer Ingelheim set out with a vision to transform the world of respiratory care. 2021 marks the company looks back on 100 years of pushing the boundaries in scientific innovation.
[Finding the right inhaler for you](/content/human-health/lung-diseases/finding-right-inhaler-you "Finding the right inhaler for you"/index.html)
Finding the right inhaler for you
Contact your healthcare professional about your inhaler options
European Commission approves a new indication and an indication extension for OFEV® in children and adolescents
[Read more](/content/human-health/lung-diseases/new-indication-and-extension-ofev-children-adolescents "Read more about "European Commission approves a new indication and an indication extension for OFEV® in children and adolescents""/index.html)
CHMP recommends approval of OFEV® in children and adolescents for the treatment of a range of interstitial lung diseases
[Read more](/content/human-health/lung-diseases/chmp-recommends-approval-ofev-children-adolescents-ilds "Read more about "CHMP recommends approval of OFEV® in children and adolescents for the treatment of a range of interstitial lung diseases""/index.html)
Products
A complete overview of our products for Human Health.